Pre-made Iladatuzumab benchmark antibody ( Whole mAb ADC, anti-CD79B therapeutic antibody, Anti-AGM6/B29/IGB Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Iladatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ladiratuzumab vedotin, also known as SGN-LIV1A and anti-LIV-1 ADC, is a humanized antibody conjugated through a proteolytically cleavable linker to MMAE to Zinc transporter LIV-1 (SLC39A6).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-264-1mg	1mg	4635
GMP-Bios-ab-264-10mg	10mg	Inquiry
GMP-Bios-ab-264-100mg	100mg	Inquiry
GMP-Bios-ab-264-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Iladatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody
INN Name	Iladatuzumab
Target	CD79B
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2019
Companies	Roche
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Non-Hodgkin's lymphoma
Development Tech	na